What disease does valganciclovir/vansevir treat?

Valganciclovir is an oral deoxynucleoside analog antiviral drug that mainly inhibits the DNA polymerase of cytomegalovirus (CMV) infection and prevents viral replication, thereby being used to treat and prevent CMV-related diseases. Its indications include adult and pediatric immunocompromised patients, and is especially widely used in organ transplant populations and patients with acquired immunodeficiency syndrome (AIDS). It is mainly used to treat CMV retinitis in adult patients and to prevent CMV disease in high-risk kidney, heart, and kidney-pancreas transplant patients. If CMV retinitis is not treated in time, it may lead to irreversible vision damage. Valganciclovir can effectively protect vision and improve quality of life by inhibiting viral replication.

In pediatric patients, the use of valganciclovir is equally critical. For high-risk kidney transplant children aged 4 months to 16 years old, it can effectively prevent CMV infection and reduce the incidence of postoperative complications; for children aged 1 month to 16 years old with heart or kidney transplants, it can also be used as a preventive drug for CMV disease. These dosing regimens are administered orally, making long-term preventive treatment more convenient while reducing the risks associated with intravenous administration.

The pharmacological properties of valganciclovir determine its broad clinical application value. It specifically inhibits viral replication and has low toxicity to host cells, ensuring the safety of long-term use. In addition, valganciclovir is listed as a standard drug for CMV prevention and treatment in overseas and domestic clinical guidelines. With the popularization of organ transplantation technology and the strengthening of the management of immunodeficiency patients, this drug has become increasingly important in preventing and controlling CMV infection, and has become one of the key drug options to ensure the health of postoperative patients and reduce the incidence of complications.

In short, with its precise antiviral mechanism, oral convenience and good safety, valganciclovir provides a scientific and sustainable treatment and prevention solution for adults and pediatricsCMV high-risk patients, and is an indispensable drug in modern antiviral treatment.

Reference materials:https://go.drugbank.com/drugs/DB01610